Glucagon-like PEPTIDE-1

National Institute of Diabetes and Digestive and Kidney DiseasesUS$7.9mNational Institute of Allergy and Infectious DiseasesUS$5.4mNational Heart, Lung, and Blood InstituteUS$4.5m

• Evaluating the safety and efficacy of glucagon-like peptide-1 receptor agonists for pre-pregnancy weight management and improved pregnancy outcomes

  National Institute of Child Health and Human DevelopmentVanderbilt University Medical CenterUS$785.4k2026–2031

• Glucagon Like Peptide-1 Medicine Outcomes in Real World Patients with Type 1 Diabetes

  National Institute of Diabetes and Digestive and Kidney DiseasesAdventhealth OrlandoUS$151.8k2026–2028

• A GLIMMER of possibility? GLucagon-like Peptide-1 Receptor Agonists—Investigating their Influence on the Mind, Metabolism, and Early Risk for ADRDs in the Understanding America Study

  National Institute on AgingUniversity of Southern CaliforniaUS$6.1m2026–2027

• Networked trial emulation framework for causal effects of Glucagon-Like Peptide-1 Receptor Agonists on Mental Health Outcomes

  National Institute of Mental HealthUniversity of PennsylvaniaUS$852.2k2026–2031

• Prior Glucagon-like Peptide-1 Receptor Agonist Therapy and Pregnancy, Postpartum, and Child Cardiovascular Outcomes: A Target Trial

  National Heart, Lung, and Blood InstituteNorthwestern UniversityUS$705.4k2025–2029

• Real-World Effectiveness and Value of Glucagon-Like Peptide-1 Receptor Agonists for Prevention of Cardiovascular Disease

  National Heart, Lung, and Blood InstituteBeth Israel Deaconess Medical CenterUS$1.7m2026–2028

• Cost Offsets and Spending on Glucagon-like peptide-1 receptor agonists (GLP-1s) in a Large National Electronic Health Record Database

  National Institute of Diabetes and Digestive and Kidney DiseasesJohns Hopkins UniversityUS$766.5k2026–2031

• Evaluation of Glucagon-Like Peptide-1 Receptor Agonist on Pathophysiology of Inflammation and Atherosclerosis in Persons Living With HIV: A Multicenter Randomized Placebo-Controlled Tri

  National Heart, Lung, and Blood InstituteUniversity of California Los AngelesUS$1.3m2026–2031

• Advancing ADPKD Treatment with GLP-1RA: A Study of Glucagon-Like Peptide-1 Receptor Agonists' Efficacy, Safety, and Mechanism

  National Institute of Diabetes and Digestive and Kidney DiseasesUniversity of Colorado, DenverUS$678.4k2024–2029

• Impact of a Glucagon-Like Peptide-1 Receptor Agonist administration on SIV/HIV pathogenesis and ART

  National Institute of Diabetes and Digestive and Kidney DiseasesUniversity of Pittsburgh at PittsburghUS$773.1k2025–2030